Comparison of Two Different Dosage of GnRH Agonist As Ovulation Trigger in Oocyte Donors: a Randomized Controled Trial

Overview

Journal JBRA Assist Reprod

Specialty Reproductive Medicine

Date 2017 Aug 25

PMID 28837025

Citations 4

Authors

Sonia Morales Zarcos

Pamela Valdivieso Mejia

Carla Donado Stefani

Pascual Sanchez Martin

Fernando Sanchez Martin

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the results obtained with two different GnRH agonist dosages: 0.3mg versus 0.4mg to trigger ovulation in oocyte donor cycles.

Methods: Experimental controlled randomized trial including 40 patients from a private practice center. The patients were randomized into two groups. Group A received a single dose of Triptorelin 0.3mg (Decapeptyl®) 36hours before pick-up. Group B patients received Triptorelin 0.4mg (Decapeptyl®) before pick-up to final oocyte maturation. We evaluated the total number of oocytes collected, the number of mature oocytes and total days of ovarian stimulation.

Results: The average of total collected oocytes were 16 (Group A) versus 15 (Group B), and the mean number of mature oocytes were 13 versus 12 respectively. The only variable showing a difference was the percentage of mature oocytes, which was greater in Group A, resulting in 84.6%, in contrast with those treated with 0.4mg of Triptorelin (78.6%), although these differences were not statistical significant (p=0.35). Days of stimulation did not differ between groups. No cases of empty follicle syndrome were reported.

Conclusions: We found that an increase from 0.3 to 0.4mg of triptorelin in an oocyte donation program might not improve outcomes. Nevertheless, more studies might be necessary, not only in oocyte donors but in sterile women as well, to evaluate how GnRH agonist dosage could affect the results among other factors.

Citing Articles

Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial.

Hashemi S, Hafezi M, Arabipoor A, Zareei M, Vesali S, Eftekhari-Yazdi P Int J Fertil Steril. 2024; 18(Suppl 1):48-54.

PMID: 39033370 PMC: 11263846. DOI: 10.22074/ijfs.2023.2008905.1513.

Factors influencing the number of mature oocytes and cryopreservable blastocysts in hyperresponder patients triggered with a GnRH analog.

Kahraman S, Sahin Y, Duzguner I, Duzguner S J Assist Reprod Genet. 2023; 40(2):407-416.

PMID: 36600075 PMC: 9935779. DOI: 10.1007/s10815-022-02702-x.

Prediction, assessment, and management of suboptimal GnRH agonist trigger: a systematic review.

Ganer Herman H, Horowitz E, Mizrachi Y, Farhi J, Raziel A, Weissman A J Assist Reprod Genet. 2022; 39(2):291-303.

PMID: 35306603 PMC: 8956771. DOI: 10.1007/s10815-021-02359-y.

Oocyte competence is independent of the ovulation trigger adopted: a large observational study in a setting that entails vitrified-warmed single euploid blastocyst transfer.

Cimadomo D, Vaiarelli A, Petriglia C, Fabozzi G, Ferrero S, Schimberni M J Assist Reprod Genet. 2021; 38(6):1419-1427.

PMID: 33661465 PMC: 8266953. DOI: 10.1007/s10815-021-02124-1.

References

Bodri D, Guillen J, Galindo A, Mataro D, Pujol A, Coll O . Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2008; 91(2):365-71. DOI: 10.1016/j.fertnstert.2007.11.049. View

Tarlatzis B, Fauser B, Kolibianakis E, Diedrich K, Rombauts L, Devroey P . GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006; 12(4):333-40. DOI: 10.1093/humupd/dml001. View

Blazquez A, Guillen J, Colome C, Coll O, Vassena R, Vernaeve V . Empty follicle syndrome prevalence and management in oocyte donors. Hum Reprod. 2014; 29(10):2221-7. DOI: 10.1093/humrep/deu203. View

Hoff J, Quigley M, Yen S . Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983; 57(4):792-6. DOI: 10.1210/jcem-57-4-792. View

Humaidan P, Papanikolaou E, Tarlatzis B . GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009; 24(10):2389-94. DOI: 10.1093/humrep/dep246. View

Whelan 3rd J, Vlahos N . The ovarian hyperstimulation syndrome. Fertil Steril. 2000; 73(5):883-96. DOI: 10.1016/s0015-0282(00)00491-x. View

Humaidan P, Papanikolaou E, Kyrou D, Alsbjerg B, Polyzos N, Devroey P . The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online. 2011; 24(2):134-41. DOI: 10.1016/j.rbmo.2011.11.001. View

Castillo J, Dolz M, Bienvenido E, Abad L, Casan E, Bonilla-Musoles F . Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online. 2010; 20(2):175-81. DOI: 10.1016/j.rbmo.2009.11.018. View

Buckett W, Bentick B, Shaw R . Induction of the endogenous gonadotrophin surge for oocyte maturation with intra-nasal gonadotrophin-releasing hormone analogue (buserelin): effective minimal dose. Hum Reprod. 1998; 13(4):811-4. DOI: 10.1093/humrep/13.4.811. View

10.

Castillo J, Garcia-Velasco J, Humaidan P . Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. J Assist Reprod Genet. 2012; 29(3):249-53. PMC: 3288136. DOI: 10.1007/s10815-011-9704-8. View

11.

Babayof R, Margalioth E, Huleihel M, Amash A, Zylber-Haran E, Gal M . Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006; 21(5):1260-5. DOI: 10.1093/humrep/dei475. View

12.

Damewood M, Shen W, Zacur H, Schlaff W, Rock J, Wallach E . Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril. 1989; 52(3):398-400. DOI: 10.1016/s0015-0282(16)60906-8. View

13.

Andersen C, Leonardsen L, Ulloa-Aguirre A, Barrios-de-Tomasi J, Moore L, Byskov A . FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod. 1999; 5(8):726-31. DOI: 10.1093/molehr/5.8.726. View

14.

Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E . Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; 44(6):430-40. DOI: 10.1097/00006254-198906000-00004. View

15.

Griesinger G, Diedrich K, Devroey P, Kolibianakis E . GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2005; 12(2):159-68. DOI: 10.1093/humupd/dmi045. View

16.

Zelinski-Wooten M, Hutchison J, Hess D, Wolf D, Stouffer R . Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod. 1995; 10(7):1658-66. DOI: 10.1093/oxfordjournals.humrep.a136151. View

17.

Emperaire J, Parneix I, Ruffie A . Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reprod Biomed Online. 2004; 9(1):22-7. DOI: 10.1016/s1472-6483(10)62105-0. View

18.

Bodri D, Guillen J, Trullenque M, Schwenn K, Esteve C, Coll O . Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril. 2009; 93(7):2418-20. DOI: 10.1016/j.fertnstert.2009.08.036. View

19.

Radesic B, Tremellen K . Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011; 26(12):3437-42. DOI: 10.1093/humrep/der333. View

20.

Humaidan P, Bredkjaer H, Bungum L, Bungum M, Grondahl M, Westergaard L . GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005; 20(5):1213-20. DOI: 10.1093/humrep/deh765. View